ZDA
RARE icon

Zweig-DiMenna Associates’s Ultragenyx Pharmaceutical RARE Stock Holding History

Zweig-DiMenna Associates’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-46,482
Closed -$2.63M – 317
2014
Q3 		$2.63M Buy
+46,482
New +$2.34M 0.12% 128

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Zweig-DiMenna Associates's RARE Position: Q4 2014 in Review

Zweig-DiMenna Associates sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2014, closing a stake of 46,482 shares — an estimated $2.63M sold.

Zweig-DiMenna Associates first reported a position in RARE in Q3 2014 and held it in 1 quarter. The position peaked at $2.63M in Q3 2014. 100 funds tracked by Wall St. Rank hold RARE as of Q4 2014.

  • Zweig-DiMenna Associates reported no remaining Ultragenyx Pharmaceutical position as of Q4 2014 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 46,482 Ultragenyx Pharmaceutical shares in Q4 2014, an estimated $2.63M.
  • Zweig-DiMenna Associates first reported a position in Ultragenyx Pharmaceutical in Q3 2014 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Ultragenyx Pharmaceutical position peaked at $2.63M in Q3 2014.
  • 100 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2014.

Based on Zweig-DiMenna Associates's 13F filing for Q4 2014, filed 12 Feb 2015.